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Abstract
Background: C/EBPα is a transcription factor essential for terminal differentiation of several cell
types. It has not known if C/EBPα protein is expressed and functions in the prostate gland.
Methods: The presence of C/EBPα in normal and cancerous prostate epithelium was examined
by immunochemistry. Over expression of C/EBPα in LNCaP cells was conducted with retrovirus-
mediated transduction. PSA expression was examined by RT-PCR and western blot and PSA
promoter activity by luciferase reporter assay.
Results: In normal prostate C/EBPα was expressed in the basal layer of the epithelium. In prostate
cancer C/EBPα was detected at low levels throughout the cancers and in advanced prostate cancer
C/EBPα expression was associated with decreased expression of AR and PSA. Overexpression of
C/EBPα inhibited epigenetically PSA expression and was accompanied by the loss of expression of
AR. Transient increase of C/EBPα inhibited the PSA promoter/enhancer activity independently of
expression of AR.
Conclusion: In LNCaP cells C/EBPα over expression inhibits expression of PSA by AR -dependent
and independent mechanisms and by extinguishing AR expression provides a model for hormonal
independent cell growth.
Background
The CCAAT/enhancer binding proteins (C/EBPs) are a
family of transcription factors that regulate cellular differ-
entiation in a variety of tissues [1]. The C/EBP transcrip-
tion factors consist of an activation domain, a DNA-
binding basic region, and a leucine-rich dimerization
domain. The structure of C/EBPα and its isoforms has
been well described. The predominant isoform is a 42 kDa
protein with three transactivation domains in the N-ter-
minal portion of the protein. A second isoform is a 30-
kDa protein formed from a downstream initiation site
that alters the transactivation domain. Both isoforms con-
tain the same dimerization and DNA-binding domains
and are influential in controlling terminal differentiation
and growth of a variety of cells [2,3]. C/EBPα is expressed
in numerous tissues with the highest expression in the
placenta, liver, lung, skeletal muscle, pancreas, small
intestine, colon and peripheral blood leukocytes. The C/
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EBPs in general are important regulators of cellular differ-
entiation and determinants of terminal cell function. C/
EBPα in particular is required for myeloid differentiation;
mice deficient in C/EBPα have an early block in granulo-
cyte maturation with a lack of expression of the G-CSF
receptor[4,5]. The role of C/EBPα in hematopoietic differ-
entiation is complex as at the same time that C/EBPα
induces granulocyte differentiation while erythroid differ-
entiation is inhibited [6]. C/EBPα plays a role in hepato-
cytes and adipocytes mediating cell cycle arrest and
transcription of hepatic-specific and adipose-specific
genes respectively. C/EBPα interacts with regulators of cell
cycle expression such as cdk2 and cdk4, directly interacts
with E2F, and represses c-Myc expression with a resultant
inhibition of adipocytes, hepatocyte, and granulocyte
proliferation and induction of terminal differentiation [7-
9]. In view of the expression of C/EBPα in terminally dif-
ferentiated tissues and its role in regulating cell growth it
is attractive to examine whether abnormalities of expres-
sion of C/EBPα have a role in carcinogenesis. Recently, C/
EBPα has been shown to be important in a subset of
patients with acute myelogenous leukemia. In patients
with a t(8;21) translocation the resulting AML1-ETO
fusion protein blocks C/EBPα expression and restoration
of C/EBPα expression restores granulocyte differentiation
[10]. In other patients with morphologically similar
leukemias, but without the t(8;21) translocation, hetero-
zygous mutations in C/EBPα result in the production of
an amino terminus truncated protein that acts in a domi-
nant negative manner to block C/EBPα DNA binding [2].
The resulting lack of transactivation of granulocyte target
genes gives rise to the characteristic loss of differentiation
seen in acute myelogenous leukemia.
The presence of C/EBPα in normal prostate tissue [11]
and the role of C/EBPα in the regulation of differentiation
and growth in other tissues raises the issues as to whether
C/EBPα is important in normal prostatic differentiation
and if aberrations of expression of C/EBPα are seen in
prostate cancer. Significant levels of C/EBPα mRNA can be
detected in the prostate [11,12]. While only one silent
mutation of C/EBPα has been found in 33 prostate can-
cers [13] increased expression of C/EBPα RNA in cancer-
ous prostate epithelium versus normal epithelium and
stroma has been detected [14]. To understand the func-
tion of C/EBPα in the prostate we examined first the dis-
tribution of C/EBPα in normal and cancerous prostatic
epithelium. We then examined the effects of C/EBPα on
the expression of the prostate specific antigen (PSA). PSA
is a serine protease and a member of the kallkrein family.
In normal prostate, PSA is produced in secretory epithelial
cells to liquefy semen [15] and PSA is considered a marker
of prostate epithelial differentiation [16,17]. In prostate
cancer, PSA is an important biomarker for the diagnosis,
treatment evaluation, and prognosis [18,19]. An elevated
serum PSA often indicates the presence and/or recurrence
of prostate cancer [20] and high levels of serum PSA is typ-
ical of patients with hormone refractory prostate cancer.
In addition to semen liquefaction, PSA is thought to regu-
late prostate proliferation through the cleavage of insulin
growth factor binding protein-3 (IGFBP-3) to activate IGF
signaling [21-23]. Recent studies showed that PSA may
contribute to bone metastasis by enhancing adhesion of
prostate cancer cells to bone marrow endothelium and
activating latent TGFβ 2 [24]. The expression of PSA is
mainly regulated by the androgen receptor (AR)
[15,25,26]. Inhibition of AR signaling blocks the expres-
sion of PSA. The tumor suppressor genes PPAR gamma
and p53 inhibited PSA expression through AR signaling
[27,28]. PSA is also regulated by androgen-independent
mechanisms [29]. In this study, we demonstrated the
inhibition of PSA expression by C/EBPα via epigenetic
loss of AR expression and direct interaction between C/
EBPα and the PSA promoter/enhancer.
Methods
Cell culture and cell transduction by retrovirus expressing 
C/EBPα
The human prostate cancer cell line, LNCaP (ATCC, Rock-
ville, MD), was maintained in RPMI 1640 medium (Medi-
atech Cellgro, Herndon, VA) supplemented with 10 %
fetal bovine serum (FBS). LNCaP cells with stable expres-
sion of C/EBPα were established with a pantropic retrovi-
ral expression system (BD Biosciences Clontech, Palo
Alto, CA). Briefly, the full length rat C/EBPα cDNA which
shares 94 % homologuos to human C/EBPα was inserted
into the retrovirus vector pLNCX and was co-transfected
with Lipofectamine Plus (Invitrogen Life Technologies,
Inc., Carlsbad, CA) into GP2-293 packaging cells with
pVSV-G, expressing an envelope glycoprotein of the ves-
ticular stomatitis virus. After 48 hours of transfection,
medium was collected, filtered, and prostate cancer cell
lines were transduced with a mixture of virus-containing
medium and fresh medium at ratio of 1:2. Polybrene
(Sigma-Aldrich, St. Louis, MO) was added to the medium
at 8µg/ml for first 24 hours. Stable expressing clones were
selected with geneticin at 400 µg/ml (Mediatech Cellgro,
Herndon, VA) for 2–3 weeks.
Immunohistochemistry and immunofluorescence
Immunohistochemical staining of the tissue slides was
performed by deparaffinization, treatment with 4% H2O2
to remove endogenous peroxidase activity, and antigen
retrieval with 10 mM sodium citrate solution. After block-
ing the samples with 15% fetal bovine serum in phos-
phate buffer saline (PBS) for 30 min the sections were
incubated at room temperature with antibodies against C/
EBPα antibody (sc-61), androgen receptor (sc-7305), and
PSA (sc-7316) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) or against p63 (Lab Vision Co., Fremont, CA).BMC Cancer 2006, 6:158 http://www.biomedcentral.com/1471-2407/6/158
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The immunohistochemical staining was performed with
multi-link reagent and AEC substrate (BioGenex, San
Ramon, CA). For immunohistochemical staining of
human prostate tissue, archived samples were obtained
from the Department of Pathology of LSUHSC under a
LSUHSC IRB approved protocol (Protocol No:E06-110).
Luciferase reporter assay of PSA promoter/enhancer 
activity
Plasmids containing the PSA promoter and enhancer driv-
ing the luciferase reporter gene were the kind gift of Dr.
Stephen P. Balk. One plasmid contained the proximal
promoter, the distal enhancer from -6480 to +12 nucle-
otides, and had multiple androgen receptor elements
(ARE). The other plasmid contained the proximal pro-
moter from -632 to +12 nucleotides and had two ARE
sites[25,26]. Prostate cancer cell lines were grown in 24
well plates to about 70–80% confluence and were co-
transfected either with 375 ng PSA promoter/enhance or
proximal promoter-driven luciferase reporter plasmid and
0–100 ng pcDNA3-rat C/EBPα expression vector or
mutated C/EBPα [2] using Lipofectamine Plus according
to manufacturer's instruction. The cells were placed in
medium with charcoal stripped FCS, 50 nM dihydrotesto-
sterone added, and after 36 hours, the transfected cells
were lysed with Passive Lysis Solution (Promega, Madi-
son, WI). The luciferase activity was measured with the
Dual-Luciferase® reporter assay system (Promega, Madi-
son, WI) on a Monolight 2010 Luminometer (BD
PharMingen, San Diego, CA). Renilla luciferase activity
was used to normalize the transfection efficiency. The sta-
tistical significance was calculated with the unpaired Stu-
dent T-test two-tailed analysis.
Cell sorting and RT-PCR
The C/EBPα-EGFP plasmid was constructed with a full
length rat C/EBPα cDNA in the pcDNA3 vector. Briefly,
pcDNA3-C/EBPα was digested with BamH1 and Sac1 and
the insert containing C/EBPα was subcloned into pEGFP-
N2 vector at Bgl2 and Sac1 sites. LNCaP cells were tran-
siently transfected with C/EBPα-pEGFP by electropora-
tion. After 48 hours, the cells were collected by
trypsinization and sorted with the BD FACSVantage™ SE
System at λex488 and λem522. The RNA was isolated from
the sorted population of fluorescence-positive cells. RT-
PCR was used to detect PSA mRNA expression. One µg of
RNA was reversibly transcribed with Superscript™ II,
RNase H- Reverse Transcriptase (Invitrogen, CA) and PCR
was conducted with HotStarTaq DNA Polymerase (Qia-
gen, Valencia, CA) using RT product diluted at a ratio of
1:10. The primer pairs used for PSA and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were, 5'-GGTGAT-
GACTCCAGCCACGA-3'(PSA forward), 5'-GCG-
CACACACGTCATTGGAA-3' (PSA reverse), 5'-
CTACTGGCGCT GCCAAGGCT-3' (GAPDH forward),
and 5'-GCCATGAGGTCCACCACCCTGT-3' (GAPDH
reverse). The conditions for the PCR were set at 30 s at
95°, 50 s at 57°C, and 1 min. at 72°C for 32 cycles follow-
ing 15 min. at 95°C at the beginning of the PCR proce-
dure to activate the hot-start taq DNA polymerase.
Western blot analysis
Whole cell extracts from prostate cancer cell lines were
obtained with RIPA buffer (PBS, 1% Nonidet P-40 (NP-
40), 0.25% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS)) containing 1X protease inhibitor cocktail
(Roche Applied Science, Indianapolis, IN). Protein con-
centration was determined by BCA Protein Assay Kit
(Pierce Biotechnology, Rockford, IL). Cell proteins were
separated by electrophoresis on 12% SDS-PAGE, trans-
ferred to Hybond ™ ECL nitrocellulose membrane (Amer-
sham Biosciences, Piscataway, NJ), and blocked with 5%
non-fat milk in 1X TBST (10 mM Tris-HCL, pH 8.0; 150
mM NaCl; 0.05% Tween-20). The blots were then incu-
bated at room temperature with rabbit anti C/EBPα anti-
body for 2 hours, washed, and incubated with peroxidase-
conjugated secondary antibody. The signal was detected
with SuperSignal West Pico Substrate (Pierce Biotechnol-
ogy, Rockford, IL). Antibodies against C/EBPα (sc-61),
androgen receptor (sc-816 and sc-7305), PSA (sc-7638)
were purchased from Santa Cruz Biotechnology,
Inc.(Santa Cruz, CA). The antibody against the β-tubulin
(MS-719) was from Lab Vision Co. (Fremont, CA).
Cell growth analysis
Growth curves were generated by plating the retrovirus
infected cells suspended in RPMI 1640 containing 10%
FBS and 400 µg/ml of geneticin in 12-well plates at initial
cell densities of about 40,000 cells/well. Every two days
cells were collected from triplicate wells by trypsinization.
The cells were then resuspended in Isoton® II (Beckman
Coulter Company, Hialeah, FL) and counted on a Coulter
Z1 (Beckman Coulter Company, Hialeah, FL).
Results
Immunohistochemical identification of C/EBPα in normal 
and cancerous prostate cancer
In studies of altered gene expression in cancerous versus
non-cancerous prostrate epithelium, increased expression
of C/EBPα has been identified at the mRNA level in about
30 % of prostate samples [14]. To determine if altered
expression of C/EBPα also occurred at the protein level
the presence of C/EBPα was examined by immunohisto-
chemistry in tissue slides from 21 different cases of pros-
tate adenocarcinoma. In normal or hyperplastic glands C/
EBPα was detected predominately in the basal cell layer
(Figure 1A and 1E). The expression of C/EBPα in the nor-
mal glands showed a similar distribution to p63, which is
a marker of basal cells of prostate gland and potential
marker of prostate stem cells (Figure 1B). As markers ofBMC Cancer 2006, 6:158 http://www.biomedcentral.com/1471-2407/6/158
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prostate differentiation the expression of AR and PSA was
predominately localized to secretory epithelial cells at the
abluminal surface (Figure 1C and 1D). In nineteen of the
21 prostate cancer cases C/EBPα was detected albeit with
variable intensity from case to case (Figure 1F and 1G)
and often with an intensity of staining less than seen in
the basal layer of normal or hyperplastic glands. In addi-
tion, cells staining strongly for C/EBPα were often seen in
the top layer of the cancerous epithelium forming pseudo
lumen. In the 19 cases with positive staining for C/EBPα,
the staining was seen regardless of Gleason score. For
example, in a case with Gleason score 4+5 significant
amounts of C/EBPα were detected in at least 10 to 15 %
of the cancer cells (Figure 1G). Advanced cancerous
regions often displayed apparently lower amounts of AR
and PSA expression (Figure 1J and 1H) compared with AR
and PSA expression in hyperplastic glands (Figure 1I and
1D).
C/EBPα expression inhibits expression of AR and PSA
The immunohistochemistry findings in Figure 1 indicated
that C/EBPα was present in the in the basal layer of nor-
mal prostate epithelium while AR and PSA were localized
to the differentiated secretory epithelial layers. What then
is the role of expression of C/EBPα in the basal cells of
normal prostate epithelium? In contrast to the known role
of C/EBPα in other tissues is the expression of C/EBPα
inhibiting differentiation of basal cells to secretory epithe-
lium? And in the cancerous tissue is the expression of C/
EBPα affecting differentiation and proliferation? To begin
addressing these questions we tested the effect of C/EBPα
expression on AR and PSA expression in LNCaP cells, a
prostate cancer cell line that expresses both AR and PSA.
The constitutional expression of C/EBPα in the LNCaP
cells is extremely low. Hence, we introduced the C/EBPα
gene into the cells by a retroviral construct carrying the rat
C/EBPα cDNA. After selection by geneticin, two pooled
clones with constitutional expression of C/EBPα were
established from the LNCaP parental cells. The nuclear
localization of the expressed C/EBPα was demonstrated
by the western blot analysis of nuclear extracts from the
two clones (data not shown). In clone 1 C/EBPα extin-
guished expression of AR and PSA immediately. Interest-
ingly, in clone 2 with repeated passage the cells displayed
increasing expression of C/EBPα and decreasing expres-
sion of AR and PSA (Figure 2A). By the third passage AR
and PSA expression had decreased to 37% and 64%
respectively of control cells transduced with virus vector
alone and by the eighth passage expression of AR and PSA
was almost non-detectable. In addition with sequential
passages of clone 2 cells C/EBPα expression increased 1.6
fold between passage 3 and 8. Unexplained is the
increased expression of the p30 isoform of C/EBPα in
clone 2 at passage 8 while in clone 1 cells the p30 isoform
was not expressed (data not shown). The long term
Localization of C/EBPα, p63, AR and PSA in normal and can- cerous prostate epithelium Figure 1
Localization of C/EBPα, p63, AR and PSA in normal and can-
cerous prostate epithelium. Tissue sections of human pros-
tate glands were stained with antibodies to C/EBPα, p63, AR 
and PSA as detailed in the Methods. Shown are representa-
tive fields of normal and hyperplastic epithelium (panels A-E) 
and regions with cancer (panels F-J). Panels A, E, F, and G 
were stained for C/EBPα, Panels D and H were stained for 
PSA, Panel B was stained for p63, and Panel C, I, and J were 
stained for AR. Panels A-D are shown at low magnification 
(10x objective) and Panels E-J at high magnification (40x 
objective). The thin arrows indicate representative areas 
staining positively for C/EBPα in normal and cancerous 
regions. In the normal or hyperplastic epithelium C/EBPα is 
detected in the basal layer. In Panel D strong staining of PSA 
is seen at the abluminal surface of the normal prostate epi-
thelium while in Panel H weakly stained PSA is localized dif-
fusedly throughout the cancerous epithelium. In panel I the 
thick arrow indicates cells staining positively for AR. In Panel 
J weak staining of AR is seen in some nuclei.BMC Cancer 2006, 6:158 http://www.biomedcentral.com/1471-2407/6/158
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Down-regulation of the expression of AR and PSA after expression of C/EBPα in LNCaP cells Figure 2
Down-regulation of the expression of AR and PSA after expression of C/EBPα in LNCaP cells. A. As described in the Methods 
whole cell extracts were obtained from LNCaP clone 2 cells at passage 3 and passage 8 and from corresponding control cells, 
subjected to SDS-PAGE and western blot analysis for AR, PSA, C/EBPα, and β-tubulin. The two right panels show the relative 
expression of AR and PSA at passage 3 and passage 8 after densitometry analysis of the western blot was standardized to β-
tubulin expression. The open bars represent the Clone 2 cells expressing C/EBPα and the dark bars, the corresponding con-
trol LNCaP cells transduced with vector alone. B. As described in Methods growth curves were obtained for Clone 2 LNCaP 
cells transduced by retrovirus carrying C/EBPα (■ ) and control virus (▲ ) at passage 3 and passage 8.
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expression of C/EBPα decreased not only the expression
of AR and PSA but also significantly stimulated cell prolif-
eration. The C/EBPα-expressing cells at passage 8 showed
more rapid growth than the control cells (Figure 2B). To
Confirm the cell proliferation by long term expression of
C/EBPα in prostate cancer cells, we introduced the virus
carrying C/EBPα cDNA into PC3 and DU145 cells and the
increased cell proliferation was also seen in the two trans-
duced cell clones (data not shown)
The extinguished expression of AR and PSA could either
be separate phenomena or, as the PSA promoter is known
to have multiple androgen receptor response elements
(ARE), if C/EBPα decreased AR expression then PSA
expression would decrease also. To test the two possibili-
ties we first examined the effect of further increases of C/
EBPα on AR and PSA expression. To increase C/EBPα
expression we exposed the clone 2 cells to trichostatin
(TSA), an inhibitor of histone deacetylase, to activate ret-
rovirus-mediated gene expression. The addition of TSA to
the clone 2 cells for 48 hours resulted in a 7 fold increase
of C/EBPα protein (Figure 3A). Concomitant with the
increase of C/EBPα PSA expression decreased by 75 % but
AR levels remained unchanged. We then examined the
effect of transient transfection of C/EBPα on endogenous
PSA expression in LNCaP cells transfected with the C/
EBPα-pEGFP construct. Using a construct that expressed
EGFP allowed the transfected cells to be sorted by flow
cytometry. In the transfected cells the levels of PSA mRNA
in the C/EBPα-pEGFP expressing cells (Figure 3B, lane 2)
decreased by approximately 2.5-fold compared to the cells
transfected with pEGFP alone (Figure 3B, lane 1). These
results suggest that transiently increasing C/EBPα expres-
sion results in decreased endogenous PSA levels implying
that C/EBPα may directly inhibit the transcription of the
PSA gene and that the decrease in PSA may not be related
to the reduced expression of AR.
Further examination of the effects of C/EBPα expression 
on the transcriptional activity of PSA
To determine if the decreased expression of PSA was a
direct effect of C/EBPα on PSA transcription we examined
the effect of C/EBPα on expression of the PSA promoter.
For these assays we used the PSA promoter coupled to a
luciferase reporter gene. The PSA promoter consists of a
proximal promoter containing two AREs and a distal
enhancer with six AREs located about 4.2 kb upstream
from the transcription start site. For these experiments, we
used 5α-dihydrotestosterone (DHT), a nature ligand of
androgen receptor, to activate AR signaling. LNCaP cells
transfected with the PSA promoter/enhancer coupled to
the luciferase reporter were co-transfected with C/EBPα-
pEGFP or pcDNA3-C/EBPα in the presence and absence
of DHT (Figure 4A). Both of the C/EBPα constructs signif-
icantly (p < 0.01) inhibited the PSA promoter although
the pcDNA3-C/EBPα construct inhibited PSA transcrip-
tional activity more than the C/EBPα-pEGFP construct
both under basal conditions and in the presence of DHT.
The greater inhibition by pcDNA3-C/EBPα could be the
result of the C-terminus of the C/EBPα synthesized from
the pcDNA3-C/EBPα construct being unencumbered by
the EGFP moiety. The inhibition of PSA transcriptional
activity in the presence of DHT also demonstrates that C/
EBPα may affect AR signaling in activation of the PSA pro-
moter/enhancer. To exclude the inhibition of the PSA pro-
moter by C/EBPα as a non-specific artifact, we examined
the promoter activity of prostate specific membrane anti-
gen (PSMA) by co-transfection of the PMSA promoter
with the C/EBPα expression plasmid. In contrast to the
PSA promoter, the PSMA promoter was not inhibited by
the expression of C/EBPα (Figure 4B). In addition, we
examined the effect of the forced expression of C/EBPα in
the PC3 and LNCaP retrovirus transduced cell lines on lev-
els of granulocyte colony- stimulating factor (G-CSF)
receptor mRNA. C/EBPα is well known to stimulate tran-
scription of the G-CSF receptor and in the transduced PC3
and LNCaP cell lines we observed that forced expression
of C/EBPα increased the RNA level of the G-CSF receptor
by 2–6 fold (data not shown). Taken together these results
suggest that inhibition by C/EBPα of the PSA promoter/
enhancer activity is specific.
To exclude that the suppression of PSA transcription was
specific to LNCaP cells we also examined the effect of
pcDNA3-C/EBPα on the PSA promoter/enhancer in two
other prostate cancer cell lines, ALVA101 and PC3, neither
of which express AR or PSA. The ALVA101 and PC3 cells
were co-transfected with an AR expressing plasmid to
allow comparison of the effect of C/EBPα expression in
the presence of DHT. As seen in Figure 5, in both the ALVA
101 and PC3 cells pcDNA3-C/EBPα significantly inhib-
ited PSA transcription both in the absence and presence of
DHT. Indeed, the inhibition of reporter expression was
greater in the ALVA101 and PC3 cells than the LNCaP
cells even with transfection with higher amounts of C/
EBPα. In addition, the effect of C/EBPα on the proximal
PSA promoter was also examined and demonstrated that
in all three cell types, LNCaP, ALVA101, and PC3, that
transient transfection with C/EBPα decreased proximal
promoter transcription in the presence and absence of
DHT although to a lesser degree than with the full-length
promoter/enhancer (data not shown).
To examine if C/EBPα acted directly on the AR and inter-
fered with the function of the AR in androgen-dependent
signaling in the enhanced inhibition by C/EBPα of the
PSA promoter/enhancer in DHT-stimulated transcription,
varying amounts of AR expression plasmid were co-trans-
fected with luciferase reporters and C/EBPα expression
vector into LNCaP cells and transcription activation wasBMC Cancer 2006, 6:158 http://www.biomedcentral.com/1471-2407/6/158
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Expression of C/EBPα inhibits PSA expression through inhibition of the PSA promoter Figure 3
Expression of C/EBPα inhibits PSA expression through inhibition of the PSA promoter. A. Increasing expression of C/EBPα 
reduced protein levels of PSA in transduced LNCaP cells. The Clone 2 cells at passage 3 and the corresponding control cells 
were treated with 500 nM trichostatin A (TSA) for 48 hours. Whole cell protein extracts were again subjected to SDS-PAGE 
and western blot analysis performed. The expression of PSA and C/EBPα were expressed relative to β-tubulin by densitometry 
of the western blots. The results in the right panels are the means ± standard deviation of three independent experiments. For 
PSA expression a single star indicates a significant difference with a P < 0.05 (unpaired t-test) comparing C/EBPα to C/EBPα 
plus TSA. For C/EBPα expression double stars indicate a significant difference with a P < 0.01 (unpaired t-test). B. LNCaP cells 
were transiently transfected either with pEGFP-N2, the transfection control, or C/EBPα-pEGFP. After 48 hours EGFP positive 
cells were collected by cell sorting and RNA extracted from the EGFP positive cells. The PSA mRNA was amplified with RT-
PCR as detailed in the Methods. In the left panel is shown the electrophoresis pattern of the PCR products from the cells 
transfected with pGFP-N2 (lane 1) and C/EBPα-pEGFP (lane 2). A densitometric scan of the electrophoretic pattern corrected 
for levels of GAPDH shows the relative amounts of PSA mRNA in the control versus C/EBPα transfected cells (right panel) 
with the columns in the right panel representing the means of two individual PCR reactions.
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measured by luciferase activity (Figure 6). Alteration of
the amount of AR expressed did not affect the inhibition
by C/EBPα either of the full-length PSA promoter/
enhancer (Figure 6, upper panel) or the proximal PSA pro-
moter (Figure 6, lower panel). These results indicate that
inhibition by C/EBPα of androgen-dependent transcrip-
tional activation of PSA was independent of the levels of
AR expression. In additional experiments, C/EBPα could
not be co-immunoprecipitated with AR suggesting no
direct interaction between AR and C/EBPα (data not
shown).
Mutations in the C/EBPα gene have been found in the
myeloblasts of patients with acute myelogenous leuke-
mia, FAB classification M2. Mutations have been observed
to occur in both the transactivating and leucine zipper
domains of the N- and C- termini portions of the gene,
respectively. The protein products of the mutated C/EBPα
act as dominant negative suppressors of wild type C/EBPα
and block the stimulation of myeloid target genes [2]. We
examined the effect of representative mutations of C/
EBPα on PSA-luciferase activity (Figure 7). The mutation
designated D30 showed considerable inhibition of PSA-
luciferase activity while D4371, a mutation occurring in
the leucine zipper domain exhibited minimal affect on C/
EBPα inhibition of the reporter construct. These results
suggest that the C-terminal leucine zipper region of C/
EBPα is more important than the transactivating domain
in the suppression of the PSA promoter/enhancer.
Analysis of the amino acid sequence of the members of C/
EBP subfamily shows that the C-terminal leucine zipper
region is highly conserved. Hence, if the C-terminus is
essential for inhibition of the PSA promoter/enhancer,
than other members of the C/EBP subfamily should
exhibit a similar effect. We tested this hypothesis by trans-
fecting LNCaP cells with C/EBPβ and demonstrated that
human C/EBPβ, as with human C/EBPα, significantly
inhibited PSA promoter/enhancer activity (Figure 8). The
inhibition by human C/EBPβ was 91% in DHT-stimu-
lated transcription and 63% in basal transcription, respec-
tively, compared to C/EBPα which caused inhibition of
94% and 57%, respectively.
Discussion
C/EBPα is expressed in many tissues including white and
brown adipose tissue, myeloid cells, lung, prostate, ovary,
and colon [11,30]. The role of C/EBPα in adipose, mye-
loid, and hepatocyte terminal differentiation has been
well established. In myeloid cells, for example, the expres-
sion of C/EBPα is regulated and C/EBPα expression leads,
in turn, to expression of genes necessary for cell differen-
tiation and to limited myeloid proliferation [4,7,31,32].
However, all hematopoiesis is not affected similarly.
While C/EBPα stimulates the differentiation of myeloid
Inhibition of the activity of PSA promoter by C/EBPα Figure 4
Inhibition of the activity of PSA promoter by C/EBPα. A. 
LNCaP cells were transiently co-transfected with a PSA pro-
moter/enhancer-driven luciferase reporter plasmid and the 
C/EBPα expression plasmids, C/EBPα-pEGFP and pcDNA3-
C/EBPα. After transfection, cells were treated for 36 hrs 
with 50 nM 5α-dihydrotestosterone (DHT) in RPMI 1640 
medium supplemented with charcoal-stripped FCS. Cell 
extracts were collected with passive lysis solution, luciferase 
activity measured using pCMV renilla to standardize the 
transfection efficiency, and the results expressed as the mean 
relative light units ± standard deviation of 4 separate experi-
ments. Open bars, basal transcription without DHT. Dark 
bars, transcription with DHT. Open double stars, statistically 
significant basal transcription in the C/EBPα expressing cells 
compared with control cells p-value < 0.01. Dark double 
stars, statistically significant DHT-stimulated transcription in 
the C/EBPα expressing cells compared with control cells 
with p-value < 0.01. B. Expression of C/EBPα did not inhibit 
the activity of PSMA promoter. The PMSA promoter-1(2 kb) 
and promoter-2 (5 kb) in the pGL-3 luciferase reporter plas-
mid, kind gifts from Dr. Sidney R. Grimes, were co-trans-
fected with the C/EBPα expression plasmid into ALVA 101 
cells. The luciferase assay was conducted as described in 
Methods.
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cells, such as granulocytes, increased expression of C/
EBPα significantly blocks the differentiation of erythroid
precursors [6]. The regulation by C/EBPα in proliferation
and differentiation might contribute to the development
of the malignant phenotype. The aberrant expression of
C/EBPα has been described in myeloid leukemias [10,13].
In a subset of myeloid leukemias mutations of C/EBPα
result in the synthesis of abnormal proteins that act as
dominant negative proteins to block the action of C/EBPα
with a resulting block of differentiation and loss of the
limits on proliferation [2]. In other leukemias the fusion
protein formed from the AML1-ETO translocation down-
regulates transcription of the C/EBPα gene [10].
However, only to varying extents has the role of C/EBPα
in the differentiation of some of the other tissues been
defined. To even a lesser extent has the presence of aber-
rant expression of C/EBPα in malignancies of these vari-
ous organs been described. For example, C/EBPα has a
gradient of expression in the small intestine of mice with
the greatest expression in the most proximal portions of
the intestine and without any expression detected in
mouse colonic epithelium [33]. In the mouse intestine C/
EBPα was found in the epithelium of the villi and not in
the crypt cells suggesting that here too C/EBPα expression
is associated with terminal differentiation. In human
colon and colonic cancers, however, C/EBPα can be
detected suggesting that there is some species specificity
and a slight decrease of expression has been detected in
more advanced colon cancer [34]. In the rat ovary expres-
sion of C/EBPα increases with differentiation of the follic-
ular cells [35]; to date there are no reports of altered C/
EBPα expression in ovarian cancer. In addition to the
detection of mutations in C/EBPα in acute myelogenous
leukemia of subtype FAB classification M2, mutations
have been detected in myelodysplastic disorders but only
silent mutations have been detected in non-hematologic
tumors including one lung cancer and one prostate cancer
[13]. In the lung C/EBPα is expressed in the basal layer of
normal lung tissue and expression of C/EBPα is recog-
nized to contribute to type II cell differentiation [36].
However the role of expression of C/EBPα on the differen-
tiation of lung cells is still unknown.
The studies presented here provide additional informa-
tion to the study that examined C/EBPα expression by
gene array [14] and in which expression of C/EBPα RNA
was increased by three fold in cancerous prostate epithe-
lium versus normal epithelium. C/EBPα expression at the
protein level in malignant and non-malignant prostate
glands has not been previously investigated. In the nor-
mal prostate, C/EBPα is predominately expressed in the
basal layers of the epithelium with little C/EBPα detected
by immunohistochemistry in the more differentiated
secretory epithelium expressing AR and PSA. This is a dis-
Dose-dependent inhibition by C/EBPα of the activity of PSA  promoter/enhancer Figure 5
Dose-dependent inhibition by C/EBPα of the activity of PSA 
promoter/enhancer. Prostate cancer cells, ALVA101, PC3, 
and LNCaP cells were transiently transfected either with 0, 
20, or 100 ng C/EBPα in the presence (dark bars) or absence 
(open bars) of DHT. Fifty ng of the androgen receptor 
expression vector (also the kind gift of Dr. Stephen P. Balk) 
was co-transfected into the AR negative cell lines, ALVA101 
and PC3. The results are expressed as in Figure 4A with the 
double star representing a p-value < 0.01, a single star, p-
value < 0.05, and the open and dark stars representing the 
same comparisons as in Figure 4A.
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tinctly different distribution than seen in other tissues
where C/EBPα is expressed in differentiated cells. It is
interesting that in our immunohistochemistry studies,
p63 was found to co-localize with the expression of C/
EBPα in normal prostate gland. p63 is a marker of the
prostate gland basal layer cell and a potential marker for
prostate stem cells, which are characterized by active cel-
lular proliferation [37,38]. Further, in prostate cancer the
detection of C/EBPα in the basal layer was lost, but C/
EBPα staining could be detected in cancerous cells
throughout pseudoglandular structures. In advanced
prostate cancer with the loss of glandular like structures,
C/EBPα was still expressed in some cancer cells with a
similar intensity of staining as in the non-malignant epi-
thelium. Interestingly, in the immunohistochemical
staining of prostate tissue arrays for C/EBPα and AR, the
ratio of C/EBPα to androgen receptor expression
increased with increasing Gleason scores (data not
shown) supporting our observation that forced overex-
pression of C/EBPα in LNCaP cells induced loss of AR
expression.
To address the questions derived from our immunohisto-
chemical staining, we first selected the PSA promoter/
enhancer as a molecular marker to investigate the role of
C/EBPα in the prostate. PSA seemed a reasonable choice:
PSA is as a marker of prostate differentiation and is
expressed in the terminally differentiated epithelium lin-
ing the lumen of tubules in the normal prostate gland as
is AR; expression of PSA is androgen-dependent; and
increased levels of PSA in the serum is an important
biomarker for prostate cancer. The observation that C/
EBPα was expressed in the basal epithelium suggested that
C/EBPα may suppress PSA expression. In view of very low
level of constitutional expression of C/EBPα protein in
the LNCaP cells, a widely used prostate cancer cell line
that expresses AR and PSA, exogenous C/EBPα was
expressed by use of a retrovirus system and two pooled
clones of LNCaP cells with stable expression of C/EBPα
were established. Clone1 was found to express neither AR
nor PSA immediately upon establishment of the clone.
Clone 2 developed epigenetic loss of AR and PSA expres-
sion with serial passage. Given the rapidity in which AR
expression is lost it is unlikely that the retrovirus itself
caused the loss of AR expression. In addition, we have
examined AR and PSA expression in LNCaP cells stably
transfected with pcDNA3-C/EBPα and also noted
decreased expression of PSA and AR (data not shown).
However, the stable expression of C/EBPα introduced
with a non-virus vector could not be maintained in
LNCaP cells despite continued selection pressure with
geneticin.
In the LNCaP clones with stable expression of C/EBPα,
concomitant with the expression of C/EBPα we observed
the loss of AR expression. Both C/EBPα and AR are impor-
tant for the control of growth of prostate cells. The contin-
ued growth of the clones overexpressing C/EBPα itself was
a surprise. In lung cancer cells and other cell types restora-
tion or increased expression of C/EBPα caused growth
arrest [36]. In contrast, in the LNCaP clones expressing C/
EBPα we did not observe any signs of growth arrest. The
resistance to C/EBPα-induced cell growth arrest may have
taken place during clonal selection. However, the estab-
lishment of stable expression of C/EBPα itself in several
prostate cell lines meant that cells could escape from the
negative regulation of cell proliferation by C/EBPα. This
Increased androgen receptor expression does not block the  inhibitory effect of C/EBPα on PSA promoter activity Figure 6
Increased androgen receptor expression does not block the 
inhibitory effect of C/EBPα on PSA promoter activity. LNCaP 
cells were co-transfected with 0, 10, 100, and 200 ng of 
androgen receptor cDNA in the presence (dark bars) or 
absence (open bars) of 100 ng cDNA for C/EBPα and in the 
presence of luciferase reporter construct driven by either 
the promoter/enhancer (upper panel) or PSA proximal pro-
moter (lower panel). DHT was added at 50 nM and after 36 
hrs the luciferase activity was measured. The results 
expressed as relative light units are the means ± standard 
deviation of 3 separate experiments.
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may explain the difference of cell fates between transient
and stably expression of C/EBPα. A recent similar example
has been observed in hepatocytes where the suppression
of cell proliferation by C/EBPα is lost during oncogenesis
by dephosphorylation of C/EBPα which leads to failure of
C/EBPα to interact with cdk2 and E2F as well as sequester-
ing retinoblastoma protein [39,40]. Similar loss of the
interaction between C/EBPα and cell cycle related pro-
teins was found in established prostate cell lines (date not
shown). In addition, the expression of C/EBPα in the
actively proliferating basal cell layer of the prostate sug-
gests that C/EBPα does not cause growth arrest in normal
prostate epithelium.
The loss AR expression occurs in several prostate cancer
cell lines, such DU145, PPC1 and PC3, and occurs fre-
quently during the clinical evolution of prostate cancer
[41,42]. The data from gene expression profiles shows
that expression of AR RNA is absent in 30 to 40 % of pros-
tate cancer samples (GEO accession: GSE1431) and the
proportion of prostate cancers not expressing AR is
increased in metastatic prostate cancer (GEO acces-
sion:GSE3325). LNCaP cell lines with loss of AR expres-
sion exhibit stronger tumorgenicity and a greater
metastatic potential in xenografts than AR positive LNCaP
cells [43]. In another prostate cancer cell line that lacked
AR expression restoration of that expression restored AR-
dependent cell growth [42]. We would predict that the
loss of AR in our C/EBPα overexpressing LNCaP clones
would cause a transformation of cells from androgen-
dependent to androgen-independent growth and that the
cells would exhibit more aggressive growth, invasion, and
metatstatic potential. Indeed, our initial analysis of cell
growth showed a more rapid growth of the C/EBPα
expressing Clone 2 LNCaP cells compared with the con-
trol cells at passage 8 when AR was barely detectable. In
addition, our immunohistochemical findings of reduced
expression of AR in advanced prostate cancer specimens
especially those that express C/EBPα is in agreement with
recent demonstrations of altered AR expression especially
in androgen-independent prostate cancer [44].
The mechanism(s) for the loss of AR expression both in
prostate cell lines and prostate cancer tissue are not com-
pletely understood and expression may vary in the same
patient at different sites of recurrence [44]. Methylation of
the AR gene promoter has been reported in advanced hor-
mone-independent prostate cancer tissue [41] and the
addition of 5-Aza-2'-deoxycytidine(5-AZA) into DU145
cells with a heavily methylated AR promoter restored AR
mRNA expression [45]. In our C/EBPα overexpressing
LNCaP cells, treatment with 5-AZA at 10 µM increased
expression of AR and PSA in early passages of clone 2 but
not clone 1 cells (data not shown). However, increased
expression of AR by 5-AZA was seen in the corresponding
control cells suggesting that methylation affecting AR
expression was occurring in both C/EBPα expressing and
non-expressing cells.
The immunohistochemical result demonstrating C/EBPα
expression in the basal layer of the prostate epithelium
with no expression of PSA in these cells led us to examine
the effect of C/EBPα on the expression of the PSA pro-
moter/enhancer. The inhibition of expression was not cell
type specific as similar studies in CV1 and COS7 cells of
Effect of isoforms and a C-terminal mutation of C/EBPα on  PSA promoter activity Figure 7
Effect of isoforms and a C-terminal mutation of C/EBPα on 
PSA promoter activity. LNCaP cells were transfected with 
PSA promoter/enhancer-driven luciferase reporter construct 
and expression vectors of C/EBPα expressing the wild type 
(WT) holoprotein, a mutated C/EBPα (D30) that gives rise 
to a protein identical to the p30 isoform of C/EBPα formed 
by an alternative initiation codon, and a C-terminal mutant 
(D4371) of C/EBPα formed by a 47 amino acid insertion at 
amino acid position 351. Luciferase activity was measured as 
in Figure 4. A. Schematic representations of the p42 and p30 
isoform of C/EBPα and the C-terminal mutant protein (2). B. 
Expression of luciferase activity from the reporter construct 
after transfection with 100 ng of cDNA for C/EBPα p42 (wild 
type, WT), p30 isoform (D30), or C-terminal mutated cDNA 
(D4371) in LNCaP cells in the presence (dark bars) or 
absence (open bars) of DHT. The results expressed as rela-
tive light units are the means ± standard deviation of 3 sepa-
rate experiments. Dark double stars signify statistical 
significance at p-value < 0.01 compared with control in DHT-
stimulated transcription activity.
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co-transfection of C/EBPα and PSA promoter reporter
gene demonstrated similar results (data not shown). A
recent report shows that inhibition of PSA expression in
LNCaP cells was dependent on an interaction between AR
and C/EBPα [46] while our results indicated that the inhi-
bition was independent of any direct interaction with AR.
With transient expression of C/EBPα in prostate cells,
ALVA 101 and the non-prostate cell line CV-1 we could
not show inhibition of the MMTV promoter which con-
tains a cryptic AR (data not shown). Nor did we observe
that an increased expression of AR affected the suppres-
sion of the PSA promoter by C/EBPα. In addition, a stand-
ard search for transcription factor binding sites by TESS or
TFSEARCHING showed that more than 10 potential C/
EBPα binding sites in the PSA promoter. Preliminary stud-
ies with a gel shift assay indicated that C/EBPα could bind
to at least 3 of these sites. Therefore, direct binding of C/
EBPα to PAS promoter may explain the suppression of the
PSA promoter by C/EBPα. We can not exclude that C/
EBPα might also stimulate expression of coactivators. On
the other hand, the results also suggest that the C-terminal
leucine zipper region was more important than the trans-
activating domains.
We are beginning to explore, amongst the various genes
whose expression in prostate cancer cells is uniformly
altered by forced expression of C/EBPα, those genes that
may contribute to the loss of AR expression and which
may provide therapeutic targets for the difficult clinical
problem of hormonal independence.
Conclusion
C/EBPα was differentially displayed between normal and
cancerous prostate. Long term of stably expression of C/
EBPα in prostate cancer cells stimulates cell proliferation.
Down-regualtion of PSA expression by C/EBPα depends
on the loss of AR expression in AR posive LNCaP cells and
on the universal inhibiton of PSA promoter.
Competing interests
The author(s) declare that they have no competing inter-
est.
Authors' contributions
HY participated in development of concept and design,
performed experiments, analyzed data, draft manuscript.
HSR and DGT were involved in critically revising the man-
uscript. JG contributed to idea development, data inter-
pretation, manuscript revision, and final approval. All
authors read and approved the manuscript.
Acknowledgements
This study is supported in part by National Institute of Diabetes and Diges-
tive and Kidney Diseases Research Grant DK-41279, CA88046 and 
CA90578 from the National Cancer Institute to D.G.T., and by the Feist-
Weiller Cancer Center, Louisiana State University Health Sciences Center, 
Shreveport, LA.
References
1. Lekstrom-Himes J, Xanthopoulos KG: Biological role of the
CCAAT/enhancer-binding protein family of transcription
factors.  J Biol Chem 1998, 273(44):28545-28548.
2. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger
S, Behre G, Hiddemann W, Tenen DG: Dominant-negative muta-
tions of CEBPA, encoding CCAAT/enhancer binding pro-
tein-alpha (C/EBPalpha), in acute myeloid leukemia.  Nat
Genet 2001, 27(3):263-270.
3. Lin FT, Lane MD: CCAAT/enhancer binding protein alpha is
sufficient to initiate the 3T3-L1 adipocyte differentiation
program.  Proc Natl Acad Sci U S A 1994, 91(19):8757-8761.
4. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ,
Tenen DG: Absence of granulocyte colony-stimulating factor
signaling and neutrophil development in CCAAT enhancer
binding protein alpha-deficient mice.  Proc Natl Acad Sci U S A
1997, 94(2):569-574.
5. Zhang P, Iwama A, Datta MW, Darlington GJ, Link DC, Tenen DG:
Upregulation of interleukin 6 and granulocyte colony-stimu-
lating factor receptors by transcription factor CCAAT
enhancer binding protein alpha (C/EBP alpha) is critical for
granulopoiesis.  J Exp Med 1998, 188(6):1173-1184.
6. Cammenga J, Mulloy JC, Berguido FJ, MacGrogan D, Viale A, Nimer
SD: Induction of C/EBPalpha activity alters gene expression
and differentiation of human CD34+ cells.  Blood 2003,
101(6):2206-2214.
7. Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR,
Tenen DG: c-Myc is a critical target for c/EBPalpha in granu-
lopoiesis.  Mol Cell Biol 2001, 21(11):3789-3806.
8. Porse BT, Pedersen TA, Xu X, Lindberg B, Wewer UM, Friis-Hansen
L, Nerlov C: E2F repression by C/EBPalpha is required for adi-
pogenesis and granulopoiesis in vivo.  Cell 2001,
107(2):247-258.
9. Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, Tim-
chenko NA: C/EBPalpha arrests cell proliferation through
direct inhibition of Cdk2 and Cdk4.  Mol Cell 2001, 8(4):817-828.
10. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G,
Hiddemann W, Zhang DE, Tenen DG: AML1-ETO downregulates
the granulocytic differentiation factor C/EBPalpha in t(8;21)
myeloid leukemia.  Nat Med 2001, 7(4):444-451.
Inhibition of promoter/enhancer activity of PSA by human C/ EBPα and C/EBPβ Figure 8
Inhibition of promoter/enhancer activity of PSA by human C/
EBPα and C/EBPβ. The LNCaP cells were transfected either 
with human C/EBPα or C/EBPβ and the full-length PSA pro-
moter coupled to the luciferase reporter. Luciferase activity 
was measured in the presence (dark bars) or absence (open 
bars) of DHT as described in Figure 4. The results expressed 
as relative light units are the means ± standard deviation of 3 
separate experiments. The open and dark double stars rep-
resent P values as described in Figure 4A.
Control C/EBPα α α α C/EBPβ β β β
0
50
100
150
200
250
300
R
e
l
a
t
i
v
e
 
l
i
g
h
t
 
u
n
i
t
sBMC Cancer 2006, 6:158 http://www.biomedcentral.com/1471-2407/6/158
Page 13 of 14
(page number not for citation purposes)
11. Antonson P, Xanthopoulos KG: Molecular cloning, sequence,
and expression patterns of the human gene encoding
CCAAT/enhancer binding protein alpha (C/EBP alpha).  Bio-
chem Biophys Res Commun 1995, 215(1):106-113.
12. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P,
Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW,
Golub TR, Sellers WR: Gene expression correlates of clinical
prostate cancer behavior.  Cancer Cell 2002, 1(2):203-209.
13. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok
SH, Larsen RJ, Asou H, Miller CW, Hoelzer D, Koeffler HP: Muta-
tions in the gene encoding the transcription factor CCAAT/
enhancer binding protein alpha in myelodysplastic syn-
dromes and acute myeloid leukemias.  Blood 2002,
99(4):1332-1340.
14. Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman
L, Klacansky I, Masys D, Arden K, Goodison S, McClelland M, Wang
Y, Sawyers A, Kalcheva I, Tarin D, Mercola D: In silico dissection
of cell-type-associated patterns of gene expression in pros-
tate cancer.  Proc Natl Acad Sci U S A 2004, 101(2):615-620.
15. Balk SP, Ko YJ, Bubley GJ: Biology of prostate-specific antigen.  J
Clin Oncol 2003, 21(2):383-391.
16. Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ: Prostate
epithelial cell lines form spheroids with evidence of glandular
differentiation in three-dimensional Matrigel cultures.  Br J
Cancer 2001, 85(4):590-599.
17. Planz B, Tabatabaei S, Kirley SD, Aretz HT, Wang Q, Lin CW,
McDougal WS, Marberger M: Studies on the differentiation
pathway and growth characteristics of epithelial culture cells
of the human prostate.  Prostate Cancer Prostatic Dis 2004,
7(1):73-83.
18. Hernandez J, Thompson IM: Prostate-specific antigen: a review
of the validation of the most commonly used cancer biomar-
ker.  Cancer 2004, 101(5):894-904.
19. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes
HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ,
Coltman CAJ: Prevalence of prostate cancer among men with
a prostate-specific antigen level < or =4.0 ng per milliliter.  N
Engl J Med 2004, 350(22):2239-2246.
20. Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin
LM, Olson KB, Pienta KJ: Prostate-specific antigen doubling
time and survival in patients with advanced metastatic pros-
tate cancer.  Urology 2003, 62 Suppl 1:128-133.
21. Koistinen H, Paju A, Koistinen R, Finne P, Lovgren J, Wu P, Seppala
M, Stenman UH: Prostate-specific antigen and other prostate-
derived proteases cleave IGFBP-3, but prostate cancer is not
associated with proteolytically cleaved circulating IGFBP-3.
Prostate 2002, 50(2):112-118.
22. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM,
Hsiung HM, Becker GW, Neubauer BL: Growth regulation of pro-
static stromal cells by prostate-specific antigen.  J Natl Cancer
Inst 1999, 91(19):1663-1669.
23. Cohen P, Peehl DM, Graves HC, Rosenfeld RG: Biological effects
of prostate specific antigen as an insulin-like growth factor
binding protein-3 protease.  J Endocrinol 1994, 142(3):407-415.
24. Romanov VI, Whyard T, Adler HL, Waltzer WC, Zucker S: Prostate
cancer cell adhesion to bone marrow endothelium: the role
of prostate-specific antigen.  Cancer Res 2004, 64(6):2083-2089.
25. Kim J, Coetzee GA: Prostate specific antigen gene regulation
by androgen receptor.  J Cell Biochem 2004, 93(2):233-241.
26. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA,
Fasciana C, Chung LW, Trapman J: A 6-kb promoter fragment
mimics in transgenic mice the prostate-specific and andro-
gen-regulated expression of the endogenous prostate-spe-
cific antigen gene in humans.  Mol Endocrinol 1997,
11(9):1256-1265.
27. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP:
Down-Regulation of prostate-specific antigen expression by
ligands for peroxisome proliferator-activated receptor
gamma in human prostate cancer.  Cancer Res 2000,
60(19):5494-5498.
28. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L: p53
represses androgen-induced transactivation of prostate-spe-
cific antigen by disrupting hAR amino- to carboxyl-terminal
interaction.  J Biol Chem 2001, 276(42):38472-38479.
29. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW: Regions of
prostate-specific antigen (PSA) promoter confer androgen-
independent expression of PSA in prostate cancer cells.  J Biol
Chem 2000, 275(52):40846-40855.
30. Birkenmeier EH, Gwynn B, Howard S, Jerry J, Gordon JI, Landschulz
WH, McKnight SL: Tissue-specific expression, developmental
regulation, and genetic mapping of the gene encoding
CCAAT/enhancer binding protein.  Genes Dev 1989,
3(8):1146-1156.
31. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen
DG: CCAAT/enhancer binding protein alpha is a regulatory
switch sufficient for induction of granulocytic development
from bipotential myeloid progenitors.  Mol Cell Biol 1998,
18(7):4301-4314.
32. Slomiany BA, D'Arigo KL, Kelly MM, Kurtz DT: C/EBPalpha inhib-
its cell growth via direct repression of E2F-DP-mediated
transcription.  Mol Cell Biol 2000, 20(16):5986-5997.
33. Chandrasekaran C, Gordon JI: Cell lineage-specific and differen-
tiation-dependent patterns of CCAAT/enhancer binding
protein alpha expression in the gut epithelium of normal and
transgenic mice.  Proc Natl Acad Sci U S A 1993, 90(19):8871-8875.
34. Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, Hedin L, Enerback
S: Increased expression of the transcription factors CCAAT-
enhancer binding protein-beta (C/EBBeta) and C/EBzeta
(CHOP) correlate with invasiveness of human colorectal
cancer.  Int J Cancer 2000, 86(3):337-343.
35. Piontkewitz Y, Enerback S, Hedin L: Expression of CCAAT
enhancer binding protein-alpha (C/EBP alpha) in the rat
ovary: implications for follicular development and ovulation.
Dev Biol 1996, 179(1):288-296.
36. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG:
Down-regulation and antiproliferative role of C/EBPalpha in
lung cancer.  Cancer Res 2002, 62(2):528-534.
37. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A,
Montironi R, McKeon F, Loda M: p63 is a prostate basal cell
marker and is required for prostate development.  Am J Pathol
2000, 157(6):1769-1775.
38. Kurita T, Medina RT, Mills AA, Cunha GR: Role of p63 and basal
cells in the prostate.  Development 2004, 131(20):4955-4964.
39. Wang GL, Iakova P, Wilde M, Awad S, Timchenko NA: Liver
tumors escape negative control of proliferation via PI3K/
Akt-mediated block of C/EBP alpha growth inhibitory activ-
ity.  Genes Dev 2004, 18(8):912-925.
40. Wang GL, Timchenko NA: Dephosphorylated C/EBPalpha
accelerates cell proliferation through sequestering retino-
blastoma protein.  Mol Cell Biol 2005, 25(4):1325-1338.
41. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A,
Reznikoff CR, Bova GS, Friedl A, Jarrard DF: Methylation of the
androgen receptor minimal promoter silences transcription
in human prostate cancer.  Cancer Res 2000, 60(13):3623-3630.
42. Sigala S, Tognazzi N, Rizzetti MC, Faraoni I, Missale C, Bonmassar E,
Spano P: Nerve growth factor induces the re-expression of
functional androgen receptors and p75(NGFR) in the andro-
gen-insensitive prostate cancer cell line DU145.  Eur J Endocri-
nol 2002, 147(3):407-415.
43. Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I,
Nelson PS, Carroll JM, Roberts CTJ, Ware JL: Androgen receptor
(AR) expression in AR-negative prostate cancer cells results
in differential effects of DHT and IGF-I on proliferation and
AR activity between localized and metastatic tumors.  Pros-
tate 2004, 61(3):276-290.
44. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M,
Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA,
Pienta KJ: Androgen-independent prostate cancer is a hetero-
geneous group of diseases: lessons from a rapid autopsy pro-
gram.  Cancer Res 2004, 64(24):9209-9216.
45. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa
Y, Mizokami A, Ito H, Yatani R, Shiraishi T: Epigenetic regulation
of androgen receptor gene expression in human prostate
cancers.  Lab Invest 2000, 80(12):1789-1796.
46. Chattopadhyay S, Gong EY, Hwang M, Park E, Lee HJ, Hong CY, Choi
HS, Cheong JH, Kwon HB, Lee K: The CCAAT enhancer-binding
protein-alpha negatively regulates the transactivation of
androgen receptor in prostate cancer cells.  Mol Endocrinol
2006, 20(5):984-995.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:158 http://www.biomedcentral.com/1471-2407/6/158
Page 14 of 14
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/158/pre
pub